KURA vs. NVDA

Last updated Jun 23, 2026

KURA (Kura Oncology, Inc.) and NVDA (NVIDIA Corporation) are both stocks. KURA operates in Biotechnology (Healthcare), while NVDA operates in Semiconductors (Technology). Over the past 10 years, KURA returned 14.39%/yr vs 68.65%/yr for NVDA. At a 0.22 correlation, their price movements are largely independent.

Performance

KURA vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kura Oncology, Inc. (KURA) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KURA achieves a -0.29% return, which is significantly lower than NVDA's 12.01% return. Over the past 10 years, KURA has underperformed NVDA with an annualized return of 14.39%, while NVDA has yielded a comparatively higher 68.65% annualized return.

KURA

• 1D: 4.33%
• 1M: -7.91%
• YTD: -0.29%
• 6M: -8.07%
• 1Y: 77.09%
• 3Y*: -1.71%
• 5Y*: -13.51%
• 10Y*: 14.39%

NVDA

• 1D: -0.97%
• 1M: -2.99%
• YTD: 12.01%
• 6M: 13.73%
• 1Y: 45.24%
• 3Y*: 70.46%
• 5Y*: 61.50%
• 10Y*: 68.65%

*Multi-year figures are annualized to reflect compound growth (CAGR)

KURA vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
KURA Kura Oncology, Inc.	-0.29%	19.29%	-39.43%	15.87%	-11.36%	-57.13%	137.53%	-2.07%	-8.24%	159.32%
NVDA NVIDIA Corporation	12.01%	38.92%	171.25%	239.02%	-50.26%	125.48%	122.30%	76.94%	-30.82%	81.99%

Correlation

The correlation between KURA and NVDA is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.14
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.20
Correlation (10Y) Calculated over the trailing 10-year period	0.22
Correlation (All Time) Calculated using the full available price history since Nov 5, 2015	0.22

Fundamentals

Market Cap KURA : $918.00M NVDA : $5.09T
EPS KURA : -$3.35 NVDA : $6.53
PS Ratio KURA : 12.72 NVDA : 20.13
PB Ratio KURA : 8.51 NVDA : 26.04
Total Revenue (TTM) KURA : $71.64M NVDA : $253.49B
Gross Profit (TTM) KURA : $67.71M NVDA : $187.95B
EBITDA (TTM) KURA : -$304.14M NVDA : $192.76B

Return for Risk

KURA vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KURA

KURA Risk / Return Rank: 75
KURA Sharpe Ratio Rank: 78
KURA Sortino Ratio Rank: 77
KURA Omega Ratio Rank: 72
KURA Calmar Ratio Rank: 75
KURA Martin Ratio Rank: 72

NVDA

NVDA Risk / Return Rank: 76
NVDA Sharpe Ratio Rank: 78
NVDA Sortino Ratio Rank: 74
NVDA Omega Ratio Rank: 71
NVDA Calmar Ratio Rank: 78
NVDA Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KURA vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kura Oncology, Inc. (KURA) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	KURA	NVDA	Difference
Sharpe ratio: Return per unit of total volatility	1.29	1.29	0.00
Sortino ratio: Return per unit of downside risk	2.06	1.86	+0.20
Omega ratio: Gain probability vs. loss probability	1.23	1.22	+0.01
Calmar ratio: Return relative to maximum drawdown	1.98	2.25	-0.26
Martin ratio: Return relative to average drawdown	4.05	5.27	-1.22

KURA vs. NVDA - Sharpe Ratio Comparison

The current KURA Sharpe Ratio is 1.29, which is comparable to the NVDA Sharpe Ratio of 1.29. The chart below compares the historical Sharpe Ratios of KURA and NVDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

KURA vs. NVDA - Drawdown Comparison

The maximum KURA drawdown since its inception was -86.69%, roughly equal to the maximum NVDA drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for KURA and NVDA.

Drawdown Indicators

	KURA	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-86.69%	-89.72%	+3.03%
Max Drawdown (1Y) Largest decline over 1 year	-39.04%	-20.21%	-18.83%
Max Drawdown (3Y) Largest decline over 3 years	-76.46%	-36.88%	-39.58%
Max Drawdown (5Y) Largest decline over 5 years	-76.46%	-66.34%	-10.12%
Max Drawdown (10Y) Largest decline over 10 years	-86.69%	-66.34%	-20.35%
Current Drawdown Current decline from peak	-75.11%	-11.39%	-63.72%
Average Drawdown Average peak-to-trough decline	-47.32%	-36.16%	-11.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.10%	8.61%	+10.49%

Volatility

KURA vs. NVDA - Volatility Comparison

Kura Oncology, Inc. (KURA) has a higher volatility of 20.01% compared to NVIDIA Corporation (NVDA) at 12.78%. This indicates that KURA's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KURA	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.01%	12.78%	+7.23%
Volatility (6M) Calculated over the trailing 6-month period	41.55%	26.61%	+14.94%
Volatility (1Y) Calculated over the trailing 1-year period	60.29%	35.31%	+24.98%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.11%	51.80%	+10.31%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	70.38%	49.89%	+20.49%

Dividends

KURA vs. NVDA - Dividend Comparison

KURA has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.13%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
KURA Kura Oncology, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVDA NVIDIA Corporation	0.13%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%

Financials

Frequently Asked Questions

Can I hold both KURA and NVDA in my portfolio?

KURA and NVDA have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, KURA or NVDA?

KURA has higher volatility (20.01%) compared to NVDA (12.78%). In terms of maximum drawdown, KURA dropped -86.69% vs NVDA's -89.72%.

Which has better risk-adjusted returns?

NVDA currently has the higher Sharpe Ratio (1.29 vs 1.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.